|2.||Abdominal Pain (Pain, Abdominal)
|5.||Renal Insufficiency (Renal Failure)
|1.||Bhatia, Madhav: 3 articles (05/2009 - 04/2005)|
|2.||Li, Zhao-Shen: 2 articles (05/2015 - 01/2007)|
|3.||Guo, Xue-Gang: 2 articles (05/2015 - 01/2007)|
|4.||Gong, Biao: 2 articles (11/2014 - 01/2007)|
|5.||Golubova, Oksana: 2 articles (07/2014 - 03/2014)|
|6.||Rodríguez, Ana B: 2 articles (02/2014 - 10/2013)|
|7.||Carrasco, Cristina: 2 articles (02/2014 - 10/2013)|
|8.||Pariente, José A: 2 articles (02/2014 - 10/2013)|
|9.||Holguín-Arévalo, María S: 2 articles (02/2014 - 10/2013)|
|10.||Martín-Partido, Gervasio: 2 articles (02/2014 - 10/2013)|
01/01/1977 - "On remission, however, hyperamylasemia due to high S-amylase activity has been found. "
12/01/1990 - "Hyperamylasemia can result either from an increased rate of entry of amylase into the circulation and/or a decreased metabolic clearance of this enzyme. "
05/01/1995 - "Marked fluctuation in serum amylase, ranging from 115 to 1160% in this study, may occur in patients with macroamylasemia. "
08/01/1992 - "This study was undertaken to investigate the incidence of postoperative hyperamylasemia and amylase levels of intraperitoneal drainage in 106 patients undergoing major abdominal surgery. "
09/01/1980 - "[Studies on macroamylasemia with special reference to the components bound to amylase and follow-up of the clinical course (author's transl)]."
06/01/2000 - "In NK1-R knockout mice, the effects of cerulein on pancreatic plasma extravasation and hyperamylasemia were reduced by 60%, and pancreatic MPO by 75%, as compared to wildtype animals. "
12/01/1996 - "Marked hyperamylasemia developed immediately after cerulein administration. "
06/01/1993 - "In the group receiving both cerulein and PYY, the hyperamylasemia was attenuated with a return to basal values at 24 hours (1,206 +/- 103 U/L). "
03/01/1990 - "Marked hyperamylasemia developed in all rats immediately after administration of caerulein. "
10/01/2002 - "Caerulein significantly increased MPO activity and wet-to-dry weight ratio, produced histological evidence of edematous pancreatitis, induced plasma extravasation, and caused hyperamylasemia. "
06/01/2002 - "There was no clear correlation between hyperamylasemia and increased creatinine levels. "
10/01/1997 - "Hematological examinations revealed nonregenerative anemia, azotemia, high serum creatinine level, hypercalcemia, hyperphosphatemia, hypercholesterolemia, hyperamylasemia, and low level of total serum protein. "
01/01/1987 - "The presence of macroamylasemia can be suspected when a patient has low renal clearance of amylase relative to creatinine (Cam/Ccr). "
07/01/1987 - "Hyperamylasemia was present in 34 children; elevated amylase/creatinine clearance ratio was helpful in diagnosing ten others. "
01/01/2013 - "Urinary amylase/urinary creatinine ratio (uAm/uCr)--a less-invasive parameter for management of hyperamylasemia."
05/01/1982 - "The purpose of this study was to determine if routine isoamylase assay would provide valuable diagnostic information in patients with hyperamylasemia. "
01/01/2015 - "A hyperamylasemia was noted, and further characterised by a fractionated isoamylase test, as being predominantly of the salivary type. "
05/01/1998 - "Hyperamylasemia occurred from 6 to 24 hours after the CABG and was mainly caused by pancreatic isoamylase. "
05/01/1995 - "The most useful and accurate method for distinguishing pancreatic from salivary-type hyperamylasemia is isoamylase analysis by electrophoresis. "
08/01/1992 - "2. The isoamylase pattern of postoperative hyperamylasemia was dominant in the salivary type. "
01/01/2006 - "The incidence of hyperamylasemia was 33 patients (33.7%) in the gabexate group and 42 (43.7%) in the placebo group (P = 0.133). "
01/01/1991 - "Comparison of the mortality and morbidity between the two groups, early vs late administration of FOY, led to the following conclusions: (1) Early administration of FOY significantly improved mortality (29.4 vs 83.3%) in severe AP, although the improvement in mortality was not directly proportional to the shortening of the time lag between the onset of AP and the start of FOY, and (2) earlier administration of FOY brought about significantly earlier recovery of abdominal pain, hyperamylasemia, and leucocytosis in mild to moderate AP."
01/01/2006 - "The objective of the present study was to determine the efficacy of prophylactic administration of gabexate for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis, hyperamylasemia and pancreatic pain. "
01/01/2010 - "The usefulness of gabexate mesilate was not apparent in any of the following conditions: acute pancreatitis (control 5.7 vs. 4.8% for gabexate mesilate), hyperamylasemia (40.6 vs. 36.9%), and abdominal pain (1.7 vs. 8.9%). "
01/01/2007 - "When the RCTs were analyzed, odds ratios (OR) for gabexate mesilate were 0.67 [95% CI (0.31 to approximately 1.47), p = 0.32] for PEP, 3.78 [95% CI (0.62 to approximately 22.98), p = 0.15] for severe PEP, 0.68 [95% CI (0.19 to approximately 2.43), p = 0.56] for the case-fatality of PEP, 0.88 [95% CI (0.72 to approximately 1.07), p = 0.20] for post-ERCP hyperamylasemia, 0.69 [95% CI (0.39 to approximately 1.21), p = 0.19] for post-ERCP abdominal pain, thus indicating no beneficial effects of gabexate on acute pancreatitis, the death rate of PEP, hyperamylasemia and abdominal pain. "
04/01/1995 - "The positive effects of BN 52021 were expressed by: (1) Significant reduction of hyperamylasemia accompanied by lower malondialdehyde accumulation in pancreatic tissue; (2) Prevention of sulflhydryl groups depletion in lung tissue; (3) Diminution of necrotic and inflammatory changes in pancreatic tissue; and (4) Improvement of survival rate. "
01/01/1991 - "The effect of BN 52021 was expressed by significant reduction of pancreas edema, diminution of hyperamylasemia, lack of superoxide dismutase activity depletion, and inhibition of lipid peroxidation in pancreatic tissue. "
03/01/1995 - "Failure to identify macroamylase as the cause of unexplained but benign hyperamylasemia correctly, can lead to costly studies (e.g. "
01/01/1993 - "It is of great importance to be able to distinguish hyperamylasemia linked to a pathological condition of the pancreas from one due to the presence of the macroamylase in the serum of the patient. "
08/01/1986 - "The contribution made by macroamylase to the occurrence of hyperamylasemia of unknown origin has not been previously quantitated nor has the distribution of age and sex been identified in a large sample. "
08/01/1982 - "A rapid and simple assay to determine if macroamylase is the cause of hyperamylasemia."
05/01/1980 - "[A case of macroamylasemia --analysis of the macroamylase (author's transl)]."
|8.||Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
05/01/2015 - "This study showed that somatostatin was effective and safe for the prevention of PEP and hyperamylasemia in ERCP patients.(ClinicalTrials.gov number, NCT01431781)."
07/01/2013 - "This study aimed to examine whether high-dose, long-term continuous infusion of somatostatin can reduce the incidence of PEP and post-ERCP hyperamylasemia. "
11/01/2015 - "The beneficial effect of somatostatin, in reducing the incidence of postprocedural hyperamylasemia seems of marginal clinical significance. "
07/01/2013 - "High-dose, long-term continuous infusion (0.5 mg/h for 24 hours) of somatostatin, performed as either a pre- or post-ERCP, can reduce the incidence of hyperamylasemia, but not PEP."
07/01/2013 - "The rate of post-ERCP hyperamylasemia was 19.4% (7/36), 21.3% (10/47), and 46.3% (19/41) in the pre-ERCP somatostatin, post-ERCP somatostatin, and placebo groups, respectively (P = 0.011). "
|9.||Octreotide (Sandostatin)FDA LinkGeneric
01/01/2000 - "Prophylactic octreotide, in the regimen used in this study, does not protect against post-ERCP hyperamylasemia and hyperlipasemia. "
12/01/1994 - "Controlled trial of different dosages of octreotide in the prevention of hyperamylasemia induced by endoscopic papillosphincterotomy."
07/01/2009 - "The occurrence rate of hyperamylasemia was lower in the QYD group and the octreotide group than in the control group (P < 0.05). "
01/01/2007 - "Hyperamylasemia was assessed in 14 of 33 (42.4%) administered octreotide patients. "
01/01/2007 - "The results indicate that octreotide can prevent PEP and hyperamylasemia."
|10.||Lipase (Acid Lipase)FDA Link
01/01/1998 - "Lipase was measured in 28 patients with hyperamylasemia; 9 of 28 had hyperlipasemia (lipase > or = 380 U/L). "
03/01/1989 - "However, hyperamylasemia occurring in conjunction with abdominal signs and symptoms or elevated serum lipase was almost always pancreatic in origin. "
03/01/1989 - "Fifty-six patients (19%) were classified as having isolated hyperamylasemia because they were asymptomatic and had normal serum lipase. "
02/18/1989 - "Thus, extrapancreatic hyperamylasemia could not always be identified by detection of isoamylases or with the aid of lipase determinations. "
01/01/1998 - "Lipase assay is indicated in patients with hyperamylasemia for early diagnosis of pancreatitis. "
06/28/2015 - "PD stent placement can reduce postoperative hyperamylasemia and might be an effective and safe option to prevent PEP if the operation indications are well controlled."
08/01/2015 - "In addition, difficult cannulation (OR 1.990) and pancreatography (OR 2.009), age <60 years (OR 1.294), prior diabetes (OR 0.614), biliary duct stent placement (OR 1.884) and nasobiliary drainage (OR 1.613) were associated with developing hyperamylasemia. "
04/01/2014 - "The number of cannulations more than 4 (19 patients), (p=0.006; RR= 3.00) was associated significantly with the development of hyperamylasemia and the placing of biliary stent (14 patients), (p=0.00; RR= 0.39) was a protective factor. "
04/14/2012 - "The rate of hyperamylasemia were 30% (18/60) and 38.3% (23 of 60) in the stent and non-stent groups, respectively (P = 0.05, χ(2) test). "
02/01/2011 - "Stents also decreased the level of hyperamylasemia (WMD, -309.22; 95% CI, -350.95 to -267.49; P≤.01). "
|2.||Drug Therapy (Chemotherapy)
10/01/1990 - "After chemotherapy, the abnormal macroamylasemia and hyperglobulinemia disappeared."
10/01/1995 - "These findings are important to consider in the differential diagnosis of hyperamylasemia following post-chemotherapy retroperitoneal lymph node dissection."
12/01/2007 - "Incidence of postoperative pancreatic fistula and hyperamylasemia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy."
10/01/1995 - "Extended retraction of the pancreas during post-chemotherapy retroperitoneal lymph node dissection may cause a minor reversible injury to the pancreas expressed as hyperamylasemia, hyperlipasemia and, rarely, jaundice. "
10/01/1995 - "Postoperative hyperamylasemia was evaluated in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for testis cancer. "
10/01/1990 - "We performed this test on 67 healthy controls and 133 patients: 15 with acute pancreatitis, 53 with chronic pancreatitis (20 during painful relapse and 33 in clinical remission), 18 with pancreatic cancer, 41 with nonpancreatic disease with abdominal pain, five with macroamylasemia, and one with total pancreatectomy. "
05/01/2000 - "Grafts with prolonged preservation were more often noted by the transplant surgeon to be edematous after reperfusion, although the incidence of hyperamylasemia posttransplant did not differ between the 2 groups. "
01/01/1995 - "The mortality in cases of hyperamylasemia was similar to that found in the general liver transplant population (i.e., 23%). "
03/01/1998 - "Although the quality of the pancreas graft was not directly addressed in this study, we believe irrespective of hyperglycemia or hyperamylasemia, subjective assessment of organ quality by an experienced transplant surgeon is the most important determinant of suitability."
11/15/2002 - "Indications for biopsy were hyperglycemia (n=8), hyperamylasemia (n=3), and graft tenderness (n=1). "
03/01/1992 - "Hyperamylasemia associated with pancreatic graft arterial stenosis in combined kidney-pancreas transplantation."
|5.||Cardiopulmonary Bypass (Heart-Lung Bypass)
01/01/1992 - "In order to study the occurrence of postbypass hyperamylasemia, 75 patients undergoing cardiopulmonary bypass (CPB) were studied from March 1989 to January 1990. "
06/01/2002 - "Our results indicate that hyperamylasemia after bypass surgery is not related to the use of cardiopulmonary bypass or the mode of surgical access."
06/01/2002 - "Although hyperamylasemia has been reported in a large proportion of patients undergoing cardiac surgery with cardiopulmonary bypass, its clinical significance and pathogenetic mechanisms remain poorly understood. "
06/01/2002 - "Is hyperamylasemia after cardiac surgery due to cardiopulmonary bypass?"
02/01/1997 - "Of the patients were cardiopulmonary bypass was performed, 11.4% presented hyperamylasemia, and 8.5% of the patients without a cardiopulmonary bypass surgery (non-significant difference). "